JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

First published online September 14, 2007, 10.2967/jnumed.107.043414
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Geus-Oei, L.-F.
Right arrow Articles by Oyen, W. J.G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Geus-Oei, L.-F.
Right arrow Articles by Oyen, W. J.G.

Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer

Lioe-Fee de Geus-Oei1, Henricus F.M. van der Heijden2, Eric P. Visser1, Rick Hermsen1, Bas A. van Hoorn1, Johanna N.H. Timmer-Bonte2,3, Antoon T. Willemsen4, Jan Pruim4, Frans H.M. Corstens1, Paul F.M. Krabbe5 and Wim J.G. Oyen1

1 Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; 2 Department of Pulmonary Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; 3 Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; 4 Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands; and 5 Department of Medical Technology Assessment, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands


Figure 1
View larger version (88K):
[in this window]
[in a new window]

  		FIGURE 1.  Typical example of patient with stage IV NSCLC and tumor lesions who responded to chemotherapy. Relative to baseline (A), there is an 82% decrease in MRglu and a 65% decrease in SUV on 18F-FDG PET after 2 cycles of carboplatin/gemcitabine (B).

 

Figure 2
View larger version (11K):
[in this window]
[in a new window]

  		FIGURE 2.  Kaplan–Meier estimates for overall survival: Kaplan–Meier analysis of relationship between overall survival and {Delta}MRGlu (dichotomized using median value of –47%) (A) and {Delta}SUV (dichotomized using median value of –35%) (B).

 

Figure 3
View larger version (12K):
[in this window]
[in a new window]

  		FIGURE 3.  Kaplan–Meier estimates for progression-free survival: Kaplan–Meier analysis of relationship between progression-free survival and {Delta}MRGlu (dichotomized using median value of –47%) (A) and {Delta}SUV (dichotomized using median value of –35%) (B).

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2007 by the Society of Nuclear Medicine.